Antisense compounds, compositions and methods are provided for modulating the expression of Smad6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad6. Methods of using these compounds for modulation of Smad6 expression and for treatment of diseases associated with expression of Smad6 are provided.
Claims What is claimed is: 1. A compound 8 to 50 nucleobases in length targeted to nucleobases 40 through 57, nucleobases 99 through 116, nucleobases 156 through 173, nucleobases 180 through 197, nucleobases 219 through 236, nucleobases 286 through 303, nucleobases 411 through 428, nucleobases 537 through 554, or nucleobases 786 through 803 of a 5'-untranslated region, nucleobases 948 through 965, nucleobases 1014 through 1031, nucleobases 1033 through 1050, nucleobases 1080 through 1097, nucleobases 1277 through 1294, nucleobases 1314 through 1331, nucleobases 1427 through 1444, nucleobases 1456 through 1473, nucleobases 1729 through 1746, nucleobases 1945 through 1962, nucleobases 2001 through 2018, nucleobases 2066 through 2083, nucleobases 2162 through 2179, or nucleobases 2326 through 2343 of a coding region of a nucleic acid molecule encoding human Smad6 of SEQ ID NO: 3, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of human Smad6. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 12, 13, 19, 26, 27, 29, 40, 11, 14, 17, 21, 28, 41 or 45 which inhibits the expression of human Smad6. 4. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:26, 29 or 40. 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 6. The compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage. 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 8. The compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 9. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 10. The compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine. 11. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 13. The composition of claim 12 further comprising a colloidal dispersion system. 14. The composition of claim 12 wherein the compound is an antisense oligonucleotide. 15. A method of inhibiting the expression of human Smad6 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of human Smad6 is inhibited. 16. The compound of claim 3 which is an antisense oligonucleotide. 17. The compound of claim 16 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 18. The compound of claim 17 wherein the modified internucleoside linkage is a phosphorothioate linkage. 19. The compound of claim 16 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 20. The compound of claim 19 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 21. The compound of claim 16 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 22. The compound of claim 21 wherein the modified nucleobase is a 5-methylcytosine. 23. The compound of claim 16 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 24. A method of inhibiting the expression of human Smad6 in human cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 3 so that expression of human Smad6 is inhibited. 25. A composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 26. The composition of claim 25 further comprising a colloidal dispersion system. 27. The composition of claim 25 wherein the compound is an 